Glycomine Secures $12,000,000 Series A Funding Round

  • Feed Type
  • Date
    11/17/2016
  • Company Name
    Glycomine
  • Mailing Address
    953 Indiana Street San Francisco, CA 94107 USA
  • Company Description
    Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist.
  • Website
    http://www.glycomine.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).
  • M&A Terms
  • Venture Investor
    Sanderling Ventures
  • Venture Investor
    Chiesi Ventures

Trending on Xconomy